Rapamycin inhibits IL-2 and added cytokines receptor-dependent arresting transduction mechanisms, via action on mTOR, and thereby blocks activation of T and B cells.The approach of action of Rapamycin is to bind the cytosolic protein FK-binding protein 12 (FKBP12) in a address agnate to tacrolimus.
Unlike the tacrolimus-FKBP12 complex, which inhibits calcineurin (PP2B), the sirolimus-FKBP12 circuitous inhibits the mTOR (mechanistic (formerly mammalian) Target Of Rapamycin, rapamycin getting addition name for sirolimus) alleyway by anon bounden to mTOR Circuitous 1 (mTORC1).
more about: Rapamycin
from: Pharmaceutical Ingredients
No comments:
Post a Comment